CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

When, where, and how to target vascular inflammation in the post-CANTOS era? Select Drug-Drug Interactions With Direct Oral Anticoagulants Same-Day Discharge After Elective Percutaneous Coronary Intervention: Insights From the British Cardiovascular Intervention Society Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Editorial2019 Aug 7;40(30):2492-2494.

JOURNAL:Eur Heart J. Article Link

When, where, and how to target vascular inflammation in the post-CANTOS era?

Maffia P, Guzik TJ. Keywords: atherosclerosis; target vascular inflammation; CANTOS trial; secondary prevention; history of myocardidal infarction; IL-1 pathway

LINK


This editorial refers to ‘Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis’, by A. Vrommanetal., doi:10.1093/eurheartj/ehz008